CT Angiography: The test of the future-now.

Similar documents
The 2016 NASCI Keynote: Trends in Utilization of Cardiac Imaging: The Coronary CTA Conundrum. David C. Levin, M.D.

Current and Future Imaging Trends in Risk Stratification for CAD

Which Test When? Avoid the Stress of Stress Testing. Marc Newell, MD, FACC, FSCCT Minneapolis Heart Institute

Disclosure Information

Use of Nuclear Cardiology in Myocardial Viability Assessment and Introduction to PET and PET/CT for Advanced Users

The Emerging Role of Cardiac CT in Cardiovascular Imaging. Anthony Gemignani, MD Vermont Cardiac Network April 28, 2016

Cardiac CT Angiography

2/20/2013. Why use imaging in CV prevention? Update on coronary CTA in 2013 Coronary CTA for 1 0 prevention: pros and cons Are we there yet?

CARDIAC MULTIMODALITY IMAGING: Informing better decisions - or just costly pictures?

I have no financial disclosures

Management of Stable Ischemic Heart Disease. Vinay Madan MD February 10, 2018

CASE from South Korea

Choosing the Appropriate Stress Test: Brett C. Stoll, MD, FACC February 24, 2018

Is computed tomography angiography really useful in. of coronary artery disease?

Advanced Imaging MRI and CTA

Εξελίξεις και νέες προοπτικές στην καρδιαγγειακή απεικόνιση CT. Σταμάτης Κυρζόπουλος Ωνάσειο Καρδιοχειρουργικό Κέντρο

Physiologic Assessment by Cardiac CT

The use of Cardiac CT and MRI in Clinical Practice

Cardiology for the Practitioner Advanced Cardiac Imaging: Worth the pretty pictures?

Diagnostic and Prognostic Value of Coronary Ca Score

Diabetes and Occult Coronary Artery Disease

Imaging of the Heart Todd Tessendorf MD FACC

Non Invasive Diagnostic Modalities for Coronary Artery Disease. Dr. Amitesh Aggarwal

Malaysian Healthy Ageing Society

New Insight about FFR and IVUS MLA

Hybrid cardiac imaging Advantages, limitations, clinical scenarios and perspectives for the future

SPECT or PET for Cardiovascular Screening in High-Risk Patients

Cardiac Stress MRI: Detection of Ischemia. Disclosures: Dobutamine Stress MR. April 28, 2018

Combining Coronary Artery Calcium Scanning with SPECT/PET Myocardial Perfusion Imaging

New Challenges in Nuclear Cardiology Practice

Welcome! To submit questions during the presentation: or Text:

Multimodality Cardiac Imaging: Its Use in the Era of Value-based Reimbursement

MD F A F C A C MAS A N S C

FFR-CT Not Ready for Primetime

21st Annual Contemporary Therapeutic Issues in Cardiovascular Disease

Cardiac Viability Testing A Clinical Perspective Annual Cardiac Imaging Symposium. Lisa M Mielniczuk MD FRCPC University of Ottawa Heart Institute

CT or PET/CT for coronary artery disease

Cardiac Imaging. Kimberly Delcour, DO, FACC. Mahi Ashwath, MD, FACC, FASE. Director, Cardiac CT. Director, Cardiac MRI

New Technologies for Cardiac CT. Geoffrey D. Rubin, MD, MBA, FACR, FNASCI Duke University

Optimal testing for coronary artery disease in symptomatic and asymptomatic patients

Chest Pain Wave I. Making Dollars and Sense Out of Stress Testing

Atypical pain and normal exercise test

Disclosures. GETTING TO THE HEART OF THE MATTER WITH MULTIMODALITY CARDIAC IMAGING Organ Review Meeting 25 September. Overview

CT Coronary Angiography - Indications: From the guidelines to clinical practice

CONFUSION IN CARDIAC TESTING. Bilal Aijaz M.D FACC FSCAI

Imaging ischemic heart disease: role of SPECT and PET. Focus on Patients with Known CAD

CHRONIC CAD DIAGNOSIS

The best from Euro-Echo Ischemic heart disease. Fausto Rigo,FESC Department of Cardiology Mestre-Venezia Hospital,Italy

Calcium scoring Clinical and prognostic value

PET myocard perfusion & viability Riemer Slart

The Role of Computed Tomography in the Diagnosis of Coronary Atherosclerosis

Multisclice CT in combination with functional imaging for CAD. Temporal Resolution. Spatial Resolution. Temporal resolution = ½ of the rotation time

What the Cardiologist needs to know from Medical Images

The Value of Stress MRI in Evaluation of Myocardial Ischemia

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Test in Subjects with Suspected CAD Anatomic Study is Better

Stress Testing:Which Study is Indicated for My Patient?

Coronary Artery Imaging. Suvipaporn Siripornpitak, MD Inter-hospital Conference : Rajavithi Hospital

FFR Incorporating & Expanding it s use in Clinical Practice

Kavitha Yaddanapudi Stony brook University New York

Debate Should we use FFR? I will say NO.

Cardiac Imaging Tests

Conflict of Interest Disclosure

Pearls & Pitfalls in nuclear cardiology

CMR stress Perfusion: what's new?

CT Imaging of Atherosclerotic Plaque. William Stanford MD Professor-Emeritus Radiology University of Iowa College of Medicine Iowa City, IA

Horizon Scanning Technology Summary. Magnetic resonance angiography (MRA) imaging for the detection of coronary artery disease

Contrast-Enhanced Computed Tomography Angiography (CTA) for Coronary Artery Evaluation

Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association

Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO!

Review of Cardiac Imaging Modalities in the Renal Patient. George Youssef

Sung A Chang Department of Internal Medicine, Division of Cardiology, Sungkyunkwan University School of Medicine, Samsung Medical Center

Detailed Order Request Checklists for Cardiology

Overview. Health and economic burden of coronary artery disease (CAD) Pitfalls in care of patients suspected of having CAD

CT FFR: Are you ready to totally change the way you diagnose Coronary Artery Disease?

Troponin = 35. Objectives. Low Risk Chest Pain. Does this patient have ACS? Does this patient have ACS? Objectives

Imaging and heart failure

Evidence for Everyone: Expanding the Reach of Health Technology Assessment 2016 CADTH Symposium, April 10-12, Shaw Centre, Ottawa

Hospital, 6 Lukon Road, Lukong Town, Changhua Shien, Taiwan 505, Taiwan.

Fundamentals, Techniques, Pitfalls, and Limitations of MDCT Interpretation and Measurement

SPECT-CT: Τι πρέπει να γνωρίζει ο Καρδιολόγος

Convincing the Payers. Saurabh Jha MBBS Assistant Professor of Radiology, University of Pennsylvania

A Light in the Dark: Cardiac MRI and Risk Mitigation. J. Ronald Mikolich MD Professor of Internal Medicine Northeast Ohio Medical University (NEOMED)

Management of High-Risk CAD : Surgeons Perspective

Noninvasive Fractional Flow Reserve from Coronary CT Angiography

Testing the Asymptomatic CAD Patient: When and Why?

Chest Pain in Women ;What is Your Diagnostic Plan? No Need for Noninvasive Test

Evaluating Clinical Risk and Guiding management with SPECT Imaging

Contrast-Enhanced Computed Tomography Angiography for Coronary Artery Evaluation

Dr Chris Ellis Cardiologist, Auckland City Hospital

Potential recommendations for CT coronary angiography in athletes

Imaging congestive heart failure: role of coronary computed tomography angiography (CCTA)

MEDICAL UNIVERSITY of SOUTH CAROLINA

Computed Tomography of the Coronary Arteries

Cigna - Prior Authorization Procedure List: Radiology & Cardiology

Diagnosis of CAD S Richard Underwood

A Light in the Dark: Cardiac MRI and Risk Mitigation. J. Ronald Mikolich MD Professor of Internal Medicine Northeast Ohio Medical University (NEOMED)

Recent Advances in Nuclear Cardiology, Cardiac CT, and Cardiac MRI: Applications for CAD in the Era of Value-based Imaging

Assessment Of Myocardial Viability

Cardiac CT saves money and time as first-line heart test 4/1/2008

Transcription:

CT Angiography: The test of the future-now. Harvey S. Hahn, MD, FACC Director, Cardiovascular Fellowship Training Program Director, Non-invasive Lab Kettering Medical Center Associate Professor of Medicine Wright State Univ & Loma Linda Univ Adjunct Professor of Medicine University of Cincinnati

A look into the future Old New

A look into the future Old NOW!

CTA Computed tomography angiography. Multi-detector or MDCT (1,2,4,8,16,32,40,64, 128, & 320) Multi-slice or MSCT Dual source (128 x 2) 3-D

3-D CTA

It s not just for the heart Coronary arteries Carotids Great vessels Aorta Renals Lower extremity run-offs.

What do you get with a CTA? EF. Aortogram. Coronary anatomy. Soft plaque / amount of disease (plaque burden). Plus a look at nodes, lungs, upper GI tract.

Non-invasive coronary anatomy.

Left anterior descending (LAD)

3-D 360 o views-normal

3-D 360 o views-cad of LAD

Anomalous Coronary Artery-Cx

CTA and Prognosis Andreini et al, JACC CV Imaging 2012

A&P Anatomy versus Physiology Anatomy Looks at degree of stenosis / amount of coronary artery disease. CTA MRA Invasive cath Physiology Looks for ischemia Echo Nuclear cmr Cath IVUS vs FFR (Anatomy) v (Physiology)

For 2013 it s $482.

Another cost -Radiation exposure msv TSA backscatter scanner 0.001 1/20 Dental x-ray 0.005 0.25 CXR (PA) 0.02 1 Mammo 2 100 Head CT 2 100 Annual background radiation 3 150 Abd CT 10 500 64 slice CTA 9-15 450-750 MPI-sestamibi 9 450 MPI-Thallium 41 2050 Invasive diagnostic cath 3+ 150+ Next generation CTA?? CXR equivalents Brenner, et al, NEJM 2007 Gerber et al, Circ 2009 Einstein, JACC 2012

< 1 msv scans! Submillisievert Median Radiation Dose for Coronary Angiography with a Second- Generation 320 Detector Row CT Scanner in 107 Consecutive Patients. Marcus Y. Chen, MD, Sujata M. Shanbhag, MD and Andrew E. Arai, MD. Radiology 2013

It s FAST!

CTA-Summary PROS: Fast. Get EF and wall motion. Get a free aortogram. Triple rule out? CONS: Some radiation exposure. Contrast injection like other CTs so risk of renal dysfunction. Does not do well with rapid or irregular HR (yet).

Total radiation exposure 2.5 msv

CT perfusion protocol

What about the radiation?

LIMA to LAD graft

Why do a cardiac test? 1. Detect CAD 2. Evaluate CP/assess ischemia. 3. Risk stratify post MI 4. Prognosis 5. Asses for viability aka hibernating myocardium

The MAIN question Do I have any blocked up arteries?

CTA in the ER Observational trials and single center RCT ROMICAT 368 pts, 50% neg CT, no ACS Hollander et. al, 568 pts, no MACE w/neg CT Goldstein et. al, 197 pts, LOS & cost, no MACE Multicenter RCT - CT-STAT 699 pts at 16 sites CT vs. SPECT-MPI 54% reduction in time to diagnosis 38% cost savings MACE after negative test 2/268 CT (0.75%, 95% CI 0.09-2.7%) 1/266 SPECT-MPI (0.38%, 95% CI 0.01-2.1%)

ACRIN PA 4005: Multicenter Randomized Controlled Study of a Rapid Rule-out Strategy Using CT Coronary Angiogram Versus Traditional Care for Low-Risk ED Patients with Potential ACS Harold Litt MD-PhD University of Pennsylvania Philadelphia, PA

Results 1 1392 subjects July 2009 Nov 2011 22 removed post-randomization (most CrCl) 908 randomized to CCTA, 462 traditional care Groups well matched, 60% black

Results 2 Index visit testing 16% didn t get CT 7-33% across sites Elevated HR (27%) Similar cath rate CT higher pos rate No testing 9% vs. 36%

Results 3 - Safety No 30-day MACE in 640 pts with neg CTA 0% event rate, 95% CI 0 0.57% Secondary aims - 30-day CCTA vs. trad One serious AE in each arm Bradycardia related to meds for HR control

Results 4 Efficiency CCTA more often discharged from ED 50% vs. 23% (95% CI 21.4-33.2) LOS shorter Overall CCTA vs. trad care: 18 vs. 25 hrs* Negative testing: 12 vs. 25 hrs* Per protocol (had CCTA or stress testing) Overall 15 vs. 26 hrs* Negative CCTA or stress (trad care) 12 vs. 25 hrs* *p<0.001 More CCTA pts diagnosed with CAD 9.0 vs. 3.5% (95% CI 0-11.2)

Results 6 Resource Utilization No significant differences in 30-day resource utilization (CCTA vs. trad care) Use of Resources CCTA-based (%) Traditional Care (%) We are obtaining 1 year follow-up 95% CI for Difference Catheterization 5.1 4.2-4.8 to 6.6 Revascularizatio n 2.7 1.3-4.3 to 7.0 Repeat ED visit 8.0 7.5-5.2 to 6.2 Rehospitalization 3.1 2.4-4.9 to 6.4 Cardiologist visit 7.1 3.8-2.4 to 9.0

Time to diagnosis was shorter. 47% directly discharged from ER (vs 12%). No safety issues. Cheaper cost in the ER, but at 28 days costs caught up?

CTA vs MPI

So ~66% did NOT need to go to the cath lab!

Coronary Anatomy-best method? CTA 85 cc of dye. 1-3 msv of radiation. Just need a 18g IV. Home right after the test. Invasive cath 30 cc for coronaries 30 cc for LVgram 30 cc for aortogram TOTAL of 90 cc+. 3+ msv of radation. Arterial access. Best case home in 2 hours.

Risks of invasive testing Death Stroke / systemic embolism Renal injury (CIN-contrast induced nephropathy). Access complications Pseudoaneurysm AV fistula Retroperitoneal bleeds Limb loss

cmr PROS: No radiation exposure. EF and wall motion. Scar/viability evaluation with DCE with gad. No nephrogenic contrast injection. CONS: NFS due to gad. Takes a long time to acquire data. Loud. Claustrophobia. Patients with metallic devices are not candidates.

NSF Nephrogenic systemic fibrosis Rare occurrence in renal failure patients exposed to gadolinium. FDA warning given. Avoiding contrast is the major reason to choose cmr over CTA.

Myocardial perfusion imaging (MPI) PROS: Can be done with exercise treadmill or pharmacologic agents. Increases the sensitivity and specificity of a treadmill test. Get wall motion and EF. TID, h/l ratio are prognostic as well. CONS: Radiation exposure. 2 scans so about 4 hours total test time.

How diagnostic are nuclear scans? ~40% of MPI s are equivocal!

Why not stress echo?

PROS: No radiation. Get wall motion, EF. Stress echo Get an echo huge advantage. Can check for changes in E/E, PAP, or MR. Test completed quickly (~1 hr vs 4). CONS: Body size a factor for image quality.

Plaque composition Similar to IVUS. Ca2+-hard plaques are more stable. Dark-soft plaques with a lipid core. Can see remodeling (Glagov s phenomena). Disease progression / regression.

CTA plaque analysis

CTA vs IVUS Non-invasive. IVUS still requires dye and radiation and can physically disrupt plaques. Much more acceptable for serial measurements. Can follow both Ca2+ score as well as plaque volume. Both techniques poor for small vessels/branches so little loss of data. CTA could replace IVUS as a major research tool.

What Gold standard? Noninvasive (physiologic) studies are measured against cath FFR (physiology) now considered validation for cath. FFR validated by SPECT! Cath (anatomy) is the gold standard Cath is not perfect- Glagov phenomena

CTA and CHF The typical question in the CHF patient is is this ischemic or not? CTA can tell you the answer. Perfusion CT will be able to detect viability, but at the cost of more radiation.

CTA and CHF

Treatment vs prevention

#1 killer in the US? 1st sign of heart disease?

Non-significant plaques dominant.

Biggest bang for the buck Yusuf and Pitt, Circ 2002

Napoli JCI 1997 Palinski FASEB 2002

Only 2 things lower CRP-ASA and statins. What should you do if your pt is on both and still has a high hscrp? If nothing, and your pt is already on or will be on these meds, then why order the test in the first place?

PET Versus SPECT PET SPECT Higher resolution images Lower resolution images 95% Sensitivity/Specificity 80% Sensitivity/Specificity Rest + Stress = 30 min Rest + Stress = 240 min 7 msv dose (PET only) 13 msv dose (SPECT) Reimbursed Reimbursed Cardiac Function at Rest & Exercise Cardiac Function only at Stress PET is better and faster than SPECT period.

The regions only combo PET/CTA

PET/CTA Average radiation exposure from CTA only 8.56 msv. Total time for the test ~45 min instead of 4 hours. Average contrast load ~85 cc. Increased confidence and decreased downstream testing.

Why get a PET/CTA? Table 3. Proposed PET/CTA results clinical pathway CTA Findings PET Findings Probable Pathology Clinical Decision Normal Normal No epicardial CAD Risk factor modification Abnormal Normal Non-flow limiting CAD Medial therapy Normal Abnormal Small branch disease or preclinical decrease in flow reserve if severe symptoms Medical therapy or cath Abnormal Abnormal Flow limiting CAD Cath or medical therapy

Diagnostic strategies Hx is still critical first step for choosing strategy. Typical vs atypical CP. Degree of symptoms. Level of activity. Good CABG candidate or not. EF / viability.

The options are 1-Straight exercise treadmill. 2-Treadmill+echo (stress echo) 3-Stress-SPECT 4-Dobutamine echo 5-Dobutamine-SPECT 6-Lexiscan-SPECT 7-Dipyridamole-PET 8-CTA or 9-PET / CTA or 10-Cath

PET PROS: More energy so better pictures, esp in obese pt. Attenuation correction. Increases the sensitivity and specificity beyond that of a SPECT scan. Get wall motion and EF at rest and stress. Faster than SPECT. Less radiation. We have a generator so doses not at the mercy of outside facilities. CONS: Coverage. Cannot do with exercise (yet).

Can exercise Testing flow diagram Intermediate CP CanNOT exercise YES Plain exercise Stress test EKG Normal NO or female 1.Stress Echo 2.Stressnuc 3. CTA 1. CTA 2. SPECT 3. PET 4. PET/CTA Did this clarify things? Probably not. What question are you trying to answer? What are you going to do with the info / test results?

Money slide Atypical CP-want to try and provoke symptomstreadmill stress. Want to know if the pt has CAD or not. Don t care about symptoms or ischemia-cta. Low risk, don t want to do anything unless you have to-want high specificity-stress echo. Want to avoid all radiation-stress echo. Don t want to miss major problem-want high sensitivity-nuclear perfusion scan. Don t want to miss anything-pet/cta.

Summary No test is perfect, not even cath. Treadmill is always the best if possible. Especially for atypical CP. Echo and SPECT are similar as imaging modalities except in people with poor echo images. PET is the best. To rule out or rule in CAD, regardless of symptoms think CTA.

Stress Echo-dobutamine and exercise. Extremely safe. Thousands of pt studied. ~1/2000 adverse events. Safe within 2-3 days of MI. More specific, but not as sensitive for CAD as nuclear. Bax et al, JACC 1997

What else can you do to increase the yield of your tests? A picture is worth 1000 words! Add an imaging modality on top of the treadmill. Nuc scans and echo both increase the Sens/spec/predictive values to ~85%. Additional imaging is especially helpful in females and pt with abnl EKGs.

RESEARCH

Intro to Stats Sensitivity - Screen for disease. Specificity - Rule in for disease. Both Sens / Spec are inherent to the test itself. PPV - % results that are a true +. NPV - % results that are a true -. PPV / NPV depends on the population being tested.

The Rev. Bayes Theorem

HIV in a nun Test + - total Disease + - 95 tp 90 fp 5 fn 810 tn 100 900 Sens=tp/(tp+fn) Spec=tn/(fp+tn) PPV=tp/(all positives) NPV=tn/(all neg) HIV ELIZA is 95% sensitive and specific. How confident are you of a + test in a nun assuming a 10% dz prevalence? What is the likelihood of this being a true+? 51%!

DXV 301

Mitral valve replacement